

1 **DEXA-based Fat Mass with the Risk of Worsening Insulin Resistance in Adolescents: A 9-Year**
2 **Temporal and Mediation Study**

3 *Brief title: Fat mass with insulin resistance*

4 Andrew O. Agbaje MD, MPH^{1,2}, Christoph Saner MD, PhD^{3,4}, Jie Zhang PhD⁵, Mélanie Henderson
5 MD, PhD⁶⁻⁸, Tomi-Pekka Tuomainen MD, PhD¹

6 ¹*Institute of Public Health and Clinical Nutrition, School of Medicine, Faculty of Health Sciences,*
7 *University of Eastern Finland, Kuopio, Finland.*

8 ²*Children's Health and Exercise Research Centre, Department of Public Health and Sports Sciences,*
9 *Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.*

10 ³*Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics,*
11 *Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.*

12 ⁴*Department of Biomedical Research, University of Bern, Bern, Switzerland.*

13 ⁵*Department of Public Health, Aarhus University, DK-8000 Aarhus, Denmark*

14 ⁶*School of Public Health, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada*

15 ⁷*Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada*

16 ⁸*Research Center of Centre Hospitalier Universitaire Sainte-Justine, Montréal, QC, Canada*

17

18

19

20 **Address correspondence to:**

21 Andrew O. Agbaje, MD, MPH, FESC, Cert. Clinical Research (*Harvard*)
22 Institute of Public Health and Clinical Nutrition, School of Medicine, Faculty of Health Sciences,
23 University of Eastern Finland, Kuopio Campus.

24 Address: Yliopistoranta 1, P.O. Box 1627, 70211 Kuopio, Finland

25 E-mail: andrew.agbaje@uef.fi

26 OrCID: 0000-0001-5138-3441

27

28

29 Disclosure statement: The authors have nothing to disclose.

30

1 **Keywords:** Obesity; Pediatrics; Causality; Adiposity; Prospective Cohort Study; Type 2 Diabetes

2 **Abstract**

3 **Context:** Surrogate measures of childhood and adolescent obesity have impaired the understanding of
4 body composition's relationship with insulin resistance in the young population.

5 **Objectives:** We aim to examine the longitudinal associations of directly measured total fat mass, trunk
6 fat mass, and lean mass with the risk of hyperglycaemia, hyperinsulinemia, and insulin resistance from
7 ages 15–24 years, the mediation path through which lipids and inflammation influence insulin
8 resistance and whether increased fat mass temporally precede insulin resistance.

9 **Methods:** We studied 3160 adolescents from the Avon Longitudinal Study of Parents and Children
10 (ALSPAC), UK birth cohort, who had complete dual-energy Xray absorptiometry measure and fasting
11 blood samples at age 15 years and repeated measures at ages 17- and 24-years clinic visit. Fasting
12 glucose >6.1 mmol/L, insulin >11.78 mU/L, and homeostatic model assessment for insulin resistance
13 (HOMA-IR) $\geq 75^{\text{th}}$ percentile were categorized as hyperglycaemia, hyperinsulinemia, and high insulin
14 resistance, respectively. Longitudinal associations were examined with generalized logit-mixed effect
15 models, whilst mediation and temporal path analyses were examined using structural equation models,
16 adjusting for cardiometabolic and other lifestyle factors.

17 **Results:** Among 3160 participants (51% female), fat mass and lean mass increased linearly in both
18 males and females while glucose, insulin, and HOMA-IR had a U-shaped course from age 15 through
19 24 years. After full adjustment, each 1 kg cumulative increase in total fat mass [odds ratio 1.12 (95%
20 confidence interval 1.11 – 1.13)] and trunk fat mass [1.21 (1.19 – 1.23)] from ages 15 through 24 years
21 were associated with a progressively worsening risk of high insulin resistance as well as
22 hyperglycaemia and hyperinsulinemia. The association of increased total fat mass with increased

1 insulin resistance was partly mediated by triglycerides (9% mediation). In the temporal path analysis,
2 higher total fat mass at age 15 years was associated with higher insulin resistance at 17 years, but not
3 *vice versa*. Higher total fat mass at 17 years was bi-directionally associated with higher insulin
4 resistance at 24 years.

5 **Conclusion:** Mid-adolescence may be an optimal time for interrupting the worsening fat mass-insulin
6 resistance pathologic cycle and attenuating the risk of progressively worsening metabolic dysfunction
7 before young adulthood.

8 **Introduction**

9 The increasing rise in the prevalence of obesity in children and adolescents and the corresponding rise
10 in the prevalence of young-onset type 2 diabetes warrants effective intervention timing aiming to
11 attenuate this global health risk.¹⁻³ The World Obesity Federation estimates that a quarter of a billion
12 children and adolescents might be living with obesity by 2030.⁴ It was recently reported that sedentary
13 behaviour may independently decrease insulin sensitivity in children and adolescents at risk of obesity
14 and increased childhood body mass index has been associated with mid-adulthood cardiovascular
15 morbidities and premature mortality.⁵⁻⁷ Several studies on the relationship between childhood and
16 adolescent obesity have relied on surrogate measures of obesity such as body mass index and waist
17 circumference which does not discriminate between the effect of fat mass and lean mass on metabolic
18 alterations.^{3,6-10} A direct measure of adiposity using dual-energy Xray absorptiometry measures of fat
19 mass has been limited to cross-sectional studies and a few short-term longitudinal studies in small to
20 moderate sample-sized populations.^{8,10-12} Thus, large-scale long-term prospective studies of directly
21 measured fat mass in relation to metabolic indices are warranted to clarify the independent role of total
22 body fat mass with respect to metabolic alteration.^{2,3,9,10}

1 Moreover, it remains unknown whether increased fat mass during growth precedes metabolic
2 alterations such as insulin resistance, or if the relationship is bidirectional in an apparently health
3 community-based young population.^{8,10} A temporal relationship has public health and clinical
4 significance in providing evidence for the appropriate timing of intervention to limit obesity and
5 subsequent metabolic risks. Carefully collected long-term repeated measures of changes in exposure
6 and outcome variables may offer evidence of a potential causal relationship between exposure and
7 outcome when bolstered with biological plausibility. Whether increased fat mass exerts its effect on
8 metabolic outcomes directly or via lipid, inflammation, and blood pressure pathways is not fully known
9 and whether increased lean mass counteracts the deleterious effect of fat mass remains unclear.^{9,10,13–16}
10 It is known that fasting glucose, insulin, and insulin resistance physiologically decrease during growth
11 from mid-adolescence to young adulthood, and the vascular protective effect of this natural decline has
12 been reported.^{17,18} It is rather unknown if this physiologic decline has any role in attenuating increasing
13 fat mass during post-pubertal growth.^{3,9,10}

14 The present study, (1). examined the longitudinal associations of total fat mass, trunk fat mass, lean
15 mass, and body mass index with the cumulative risk of hyperglycaemia, hyperinsulinemia, and high
16 insulin resistance at ages 15, 17, and 24 years; (2) examined the temporal and bidirectional relationship
17 between fat mass, lean mass, and insulin resistance; (3) assessed the extent to which the longitudinal
18 associations of fat mass and lean mass with insulin resistance are mediated by lipid measures and
19 inflammation using data from the Avon Longitudinal Study of Parents and Children (ALSPAC) birth
20 cohort, England, UK.

21

22

1 **Methods**

2 **Study cohort**

3 Data were from the ALSPAC birth cohort, which investigates factors that influence childhood
4 development and growth. Pregnant women resident in Avon, UK with expected dates of delivery
5 between 1st April 1991 and 31st December 1992 were invited to take part in the study. 20,248
6 pregnancies have been identified as being eligible and the initial number of pregnancies enrolled was
7 14,541. Of the initial pregnancies, there was a total of 14,676 fetuses, resulting in 14,062 live births
8 and 13,988 children who were alive at 1 year of age. When the oldest children were approximately 7
9 years of age, an attempt was made to bolster the initial sample with eligible cases who had failed to join
10 the study originally. As a result, when considering variables collected from the age of seven onwards
11 (and potentially abstracted from obstetric notes) there are data available for more than the 14,541
12 pregnancies mentioned above. The number of new pregnancies not in the initial sample (known as
13 Phase I enrolment) that are currently represented in the released data and reflecting enrolment status at
14 the age of 24 is 906, resulting in an additional 913 children being enrolled (456, 262 and 195 recruited
15 during Phases II, III and IV respectively). The total sample size for analyses using any data collected
16 after the age of seven is therefore 15,447 pregnancies, resulting in 15,658 fetuses. Of these 14,901
17 children were alive at 1 year of age. Regular clinic visits of the children commenced at 7 years of age
18 and are still ongoing into adulthood. Study data at 24 years of age were collected and managed using
19 REDCap electronic data capture tools.¹⁹ In this study, 3160 participants who had complete directly
20 measured body composition and fasting blood sample measures at age 15 years clinic visits were
21 included. Participants were followed up until the age of 24 years. Ethical approval for the study was
22 obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.
23 Informed consent for the use of data collected via questionnaires and clinics was obtained from
24 participants following the recommendations of the ALSPAC Ethics and Law Committee at the time²⁰⁻

1 22. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004).
2 Please note that the study website contains details of all the data that is available through a fully
3 searchable data dictionary and variable search tool (<http://www.bristol.ac.uk/alspac/researchers/our->
4 [data/](http://www.bristol.ac.uk/alspac/researchers/our-data/)).

5 **Exposures: Body composition and anthropometry**

6 Body composition (total body fat mass, trunk fat mass, and total body lean mass) was assessed using a
7 dual-energy Xray absorptiometry scanner (GE Medical Systems, Madison, Wisconsin) at 15, 17, and
8 24-year clinic visits as previously described.^{23–25} Repeated dual-energy Xray absorptiometry
9 measurements for 122 children were performed on the same day, and the repeatability coefficient
10 (twice the standard deviation of the difference between measurement occasions) for body fat mass was
11 0.5 kg.^{13,24,25} Anthropometry of participants (height measured with Harpenden wall-mounted
12 stadiometer (Holtain Ltd, Crosswell, Crymch, UK) and weight to the nearest 0.1 kg at was measured
13 using Tanita TBF-401 (Model A, Tanita Corp., Tokyo, Japan electronic scale) at ages 15, 17, and 24
14 years were assessed in line with standard protocols, and body mass index was computed as weight in
15 kilograms per height in meters squared.^{23,25}

16 **Outcomes: Fasting glucose, insulin, and insulin resistance**

17 Using standard protocols, fasting blood samples at ages 15, 17, and 24 years were collected, spun, and
18 frozen at -80°C , and a detailed assessment of fasting glucose and insulin have been described
19 previously.^{23–25} Fasting insulin was measured using an ultrasensitive automated microparticle enzyme
20 immunoassay (Mercodia), which does not cross-react with proinsulin and the sensitivity of the
21 immunoassay was 0.07 mU/L.¹⁷ Participants with fasting glucose >6.1 mmol/L and insulin >11.78
22 mU/L were categorized at risk of hyperglycemia and hyperinsulinemia.^{24,26} We calculated the

1 homeostatic model assessment of insulin resistance (HOMA-IR) from (fasting insulin \times fasting
2 glucose/22.5).²⁷ HOMA-IR binary categories were grouped as ≥ 75 percentile as high and < 75
3 percentile as moderate, normal, healthy, or not high.²⁴ The Single Point Insulin Sensitivity Estimator
4 (SPISE) has been developed as a surrogate index for whole-body insulin sensitivity in adolescents.²⁸
5 SPISE index is computed as follows: $[600 \times \text{high-density lipoprotein cholesterol (HDL-c)}^{0.185} /$
6 $(\text{Triglyceride}^{0.2} \times \text{body mass index}^{1.338})]$ with fasting HDL-c and triglyceride in (mg/dL), and body
7 mass index (kg/m²).²⁸ To convert HDL-c to mg/dl, values in mmol/l were multiplied by 38.6, and
8 triglyceride to mg/dl, mmol/l values were multiplied by 88.6. The Pearson's correlation coefficients
9 between SPISE index and each of body mass index, trunk fat mass, total fat mass, and lean mass were -
10 0.90, -0.80, -0.75, and -0.37, respectively. The Pearson's correlation coefficients between HOMA-IR
11 and each of body mass index, trunk fat mass, total fat mass, and lean mass were 0.37, 0.36, 0.36, and -
12 0.03, respectively. HOMA-IR is a surrogate measure of hepatic insulin sensitivity whereas SPISE index
13 is a surrogate measure of whole-body insulin sensitivity.^{27,28}

14 **Covariates: Cardiometabolic, socioeconomic, and lifestyle factors**

15 Heart rate and blood pressure were measured with semi-automated digital monitors at ages 15, 17, and
16 24 years as previously detailed.^{23,25} A detailed assessment of fasting high-sensitivity C-reactive protein
17 (hsCRP), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c),
18 and triglyceride has been reported (coefficient of variation was $< 5\%$)^{23-25,29} At the 17-year clinic visit,
19 participants were briefly asked about their personal and family (mother, father, and siblings) medical
20 history such as a history of hypertension, diabetes, high cholesterol, and vascular disease. All
21 participants had attained puberty at the 17-year clinic visit using a time (years) to age at peak height
22 velocity objective assessment derived from Superimposition by Translation And Rotation mixed-
23 effects growth curve analysis.^{25,30}

1 The participant's mother's socioeconomic status was grouped according to the 1991 British Office of
2 Population and Census Statistics classification.³¹ Questionnaires to assess smoking behaviour were
3 administered at the 15, 17, and 24-year clinic visits. A specific question regarding whether participants
4 smoked in the last 30 days was used as an indicator of current smoking status. Sedentary time, light
5 physical activity, and moderate to vigorous physical activity were assessed with ActiGraph™ (LLC,
6 Fort Walton Beach, FL, USA) accelerometer worn on the waist for 7 consecutive days at 15-year clinic
7 visits whereas at 24 years movement behaviour was assessed using ActiGraph GT3X+ accelerometer
8 device worn for four consecutive days.³²

9 **Statistical analysis**

10 Cohort descriptive characteristics were summarized as means and standard deviation, medians and
11 interquartile ranges, or frequencies and percentages. We explored sex differences using independent t-
12 tests, Mann Whitney-U tests, or Chi-square tests for normally distributed, skewed, or dichotomous
13 variables, respectively. Multicategory variables were analysed using a one-way analysis of variance.
14 Normality was assessed by histogram curve, quantile-quantile plot, and Kolmogorov-Smirnov tests
15 with p-value <0.05. We conducted a logarithmic transformation of skewed variables and confirmed
16 normality prior to further analysis.

17 ***Analyses of longitudinal associations***

18 We examined the separate longitudinal associations of each of the 9-year cumulative total fat mass,
19 trunk fat mass, and lean mass progression (age 15 through 24 years) with the risk of each of
20 hyperglycemia, hyperinsulinemia, and high insulin resistance at ages 15, 17, and 24 years using
21 generalized linear mixed-effect models (GLMM) with logit link. The optimal model with the lowest
22 Bayesian Information Criteria was one with sex as a main effect, a random intercept modeled for the

1 participants to account for within-individual correlations. Whilst the GLMM is robust for handling
2 missing at random predictor and covariate data, we elected to additionally conduct 20 cycles of
3 multiple imputations to account for missing data. The GLMM accounted for baseline body composition
4 exposures, metabolic outcomes, and covariates and their repeated measures. For total fat mass, trunk fat
5 mass, and lean mass variable analyses, Model 1 was unadjusted. Model 2 was adjusted for sex, and
6 other time-varying covariates measured at both baseline and follow-up such as age, low-density
7 lipoprotein cholesterol, triglyceride, high sensitivity C-reactive protein, high-density lipoprotein
8 cholesterol, heart rate, in addition to systolic blood pressure, glucose, insulin, fat mass or lean mass,
9 depending on the exposure or outcome. Model 3 was an additional adjustment for lifestyle factors viz,
10 sedentary time, light physical activity, moderate to vigorous physical activity, smoking status, family
11 history of hypertension/diabetes/high cholesterol/vascular disease, and socioeconomic status.

12 *Cross-lagged temporal path analyses*

13 We used structural equation modeling with autoregressive cross-lagged design to examine the separate
14 temporal associations of total fat mass or lean mass with insulin resistance (HOMA-IR). The cross-
15 lagged models first tested the separate associations of total fat mass or lean mass at 15 years with
16 insulin resistance at 17 years. Next, the associations of insulin resistance at 15 years with total fat mass
17 or lean mass at 17 years were examined. Thereafter, we examined the separate associations of total fat
18 mass or lean mass at 17 years with insulin resistance at 24 years. Lastly, the associations of insulin
19 resistance at 17 years with total fat mass or lean mass at 24 years were examined. These models were
20 adjusted for all the covariates measured at 15 and 17 years as listed above. In the cross-lagged design,
21 the potential association could be; total fat mass or lean mass leading to insulin resistance risks, insulin
22 resistance risks leading to total fat mass or lean mass, or bidirectional associations of total fat mass or
23 lean mass with insulin resistance risks. If a path from total fat mass or lean mass at time t-1 (15 years)

1 to insulin resistance at time t-2 (17 years) reaches statistical significance (p-value<0.05), changes in the
2 earlier variables are considered to temporally precede changes in the later, and *vice versa*. Likewise, if
3 a path from total fat mass or lean mass at time t-2 (17 years) to insulin resistance at time t-3 (24 years)
4 reaches statistical significance (p-value<0.05), changes in the earlier variables are considered to
5 temporally precede changes in the later, and *vice versa*. A stronger predictive effect is determined by a
6 larger standardized regression coefficient. Error terms were included in the cross-lagged model.

7 ***Mediation path longitudinal analyses***

8 Lastly, mediating path analyses using structural equation models separately examined the mediating
9 role of cumulative lipids, hsCRP, and fat mass or lean mass depending on the exposure on the
10 longitudinal associations of cumulative fat mass and lean mass with insulin resistance from age 15
11 through 24 years. The mediation analysis was conducted in line with the Guideline for Reporting
12 Mediation Analyses of Randomized Trials and Observational Studies (AGReMA).³³ Analyses were
13 adjusted for age, sex, HDL-c, LDL-c, triglyceride, hsCRP, family history of hypertension and
14 cardiovascular diseases, smoking status, heart rate, systolic blood pressure, sedentary time, light
15 physical activity, moderate-to-vigorous physical activity, total fat mass, or lean mass depending on the
16 exposure. The path models had three equations per regression analysis: the longitudinal associations of
17 cumulative total fat mass or lean mass with cumulative lipids or inflammation (Equation 1); the
18 longitudinal associations of cumulative lipids or inflammation with insulin resistance (Equation 2); and
19 the longitudinal associations of cumulative total fat mass or lean mass with insulin resistance (Equation
20 3, total effect), and Equation 3' (direct effect) accounted for the mediating role of cumulative lipids or
21 inflammation on the longitudinal associations of cumulative total fat mass or lean mass with
22 cumulative insulin resistance. The proportion of mediating or suppressing roles was estimated as the
23 ratio of the difference between Equation 3 and Equation 3' or the multiplication of Equations 1 and 2

1 divided by Equation 3 and expressed in percentage. A mediating or indirect role is confirmed when
2 there are statistically significant associations between (a) the predictor and mediator, (b) the predictor
3 and outcome, (c) the mediator and outcome, and (d) the longitudinal association between the predictor
4 and outcome variable was attenuated upon inclusion of the mediator.³⁴ However, when the magnitude
5 of the longitudinal association between the predictor and outcome is increased upon inclusion of a third
6 variable, a suppression is confirmed.³⁴ This means that suppression occurs when the mediational path
7 has an opposite effect, i.e. instead of a decrease in the point estimate of the direct effect between an
8 exposure and an outcome in relation to the total effect, there is rather an increase in the direct effect
9 above the total effect's point estimate.³⁴ We considered a statistically significant mediation or
10 suppression of <1% as minimal, and $\geq 1\%$ as partial. Path analyses were conducted with 1,000
11 bootstrapped samples.^{35,36}

12 Collinearity diagnoses were performed and accepted results with a variance inflation factor <2,
13 considered differences and associations with a 2-sided p-value <0.05 as statistically significant, and
14 drew conclusions based on effect estimates and their confidence intervals (CI). Covariates were
15 identified based on previous studies^{13,17,24,31,37-40} We applied Sidak-correction for potential multiple
16 comparisons. Analyses involving 30% of a sample of 10,000 ALSPAC children at 0.8 statistical power,
17 0.05 alpha, and 2-sided p-value would show a minimum detectable effect size of 0.053 standard
18 deviations if they had relevant exposure for a normally distributed quantitative variable.⁴¹ All statistical
19 analyses were performed using SPSS statistics software, Version 27.0 (IBM Corp, Armonk, NY, USA),
20 and mediation analyses structural equation modeling was conducted using IBM AMOS version 27.0.

21

22

1 **Results**

2 Altogether 3160 participants who had complete body composition and metabolic outcomes at age 15
3 years were included. From age 15 through 24 years, fat mass and lean mass increased linearly in both
4 males and females (Table 1 and Figure 1). Fasting glucose, insulin, and HOMA-IR had a U-shaped
5 increase from age 15 through 24 years with the nadir at age 17 years (Table 1 and Figure 1). The
6 prevalence of obesity increased five-fold in both males and females during growth from age 15 to 24
7 years. Other characteristics are described in Table 1.

8 **Longitudinal associations of body composition with the risk of metabolic alteration**

9 After full adjustments for lifestyle and cardiometabolic factors, cumulative total fat mass [odds ratio
10 1.12 (95% confidence interval 1.11 – 1.13)], trunk fat mass [1.21 (1.19 – 1.23)], and body mass index
11 [1.26 (1.23 – 1.27)] from ages 15 through 24 years were associated with a progressively worsening risk
12 of high insulin resistance, as well as hyperglycaemia and hyperinsulinemia (Table 2). Cumulative
13 increase in lean mass [0.98 (0.98 – 0.99)] was associated with a lower risk of high insulin resistance, as
14 well as hyperinsulinemia but there was no statistically significant association with hyperglycemia
15 (Table 2).

16
17 Among males and females, increased total fat mass, trunk fat mass, and body mass index during growth
18 from age 15 to 24 years were associated with increased fasting insulin concentration and insulin
19 resistance but with decreased fasting glucose (Supplemental Table 1).⁴² Increased lean mass was
20 associated with increased fasting insulin and insulin resistance in females but not in males
21 (Supplemental Table 1).⁴²

22
23 Among normal weight and participants with overweight/obesity, increased total fat mass and trunk fat
24 mass during growth from age 15 to 24 years were associated with increased fasting insulin

1 concentration and insulin resistance but with decreased fasting glucose (Supplemental Table 2).⁴²
2 Increased lean mass was associated with increased fasting insulin and insulin resistance among
3 participants who were overweight/obese but with decreased insulin resistance in normal-weight
4 participants (Supplemental Table 2).⁴²

5
6 Cumulatively increased total fat mass was inversely associated with SPISE index from age 15 to 24
7 years (unstandardized regression coefficient -8.26 (95% confidence interval -8.37 – -8.16), $p < 0.0001$.
8 Cumulatively increased trunk fat mass was inversely associated with SPISE index from age 15 to 24
9 years (-7.43 (-7.52 – -7.34), $p < 0.0001$. Cumulatively increased body mass index was inversely
10 associated with SPISE index from age 15 to 24 years (-28.76 (-30.96 – -26.57), $p < 0.0001$.
11 Cumulatively increased lean mass was inversely associated with SPISE index from age 15 to 24 years
12 (-2.65 (-3.02 – -2.28), $p < 0.0001$.

14 **Temporal path associations of fat mass or lean mass with insulin resistance**

15 Total fat mass, lean mass, and insulin resistance (HOMA-IR) at age 15 years were directly associated
16 with their individual variables at age 17 years (Table 3 and Figure 1). Moreover, total fat mass, lean
17 mass, and insulin resistance at age 17 years were directly associated with their respective variables at
18 age 24 years (Table 3 and Figure 1).

19
20 Higher total fat mass at 15 years was associated with higher insulin resistance at 17 years, but higher
21 insulin resistance at 15 years was not associated with higher total fat mass at 17 years (Table 3 and
22 Figure 1). Higher total fat mass at 17 years was bi-directionally associated with higher insulin
23 resistance at 24 years (Table 3 and Figure 1). Higher lean mass at 15 years was associated with lower
24 insulin resistance at 17 years, but higher insulin resistance at 15 years was not associated with higher

1 lean mass at 17 years (Table 3 and Figure 1). Higher lean mass at 17 years was bi-directionally
2 associated with higher insulin resistance at 24 years (Table 3 and Figure 1).

3
4 **Mediating or suppressing effects of total fat mass, lean mass, insulin resistance, lipids, and**
5 **inflammation in the longitudinal associations of ST, LPA, and MVPA with systolic and diastolic**
6 **BP**

7 Cumulative HDL-c, LDL-c, triglyceride, systolic blood pressure, and lean mass partially mediated (1.3
8 – 9.2% mediation) the longitudinal associations of increased fat mass with increased insulin resistance
9 (Table 4 and Figure 2) after full adjustments for covariates. There was no statistically significant
10 mediating effect of hsCRP on the relationship of fat mass with insulin resistance.

11
12 With a mediating effect of 41%, LDL-c partially mediated the associations of cumulatively increased
13 lean mass with decreased insulin resistance (Table 4 and Figure 2). Cumulative increased fat mass
14 strongly mediated (85% mediation) the longitudinal associations of increased lean mass with increased
15 insulin resistance (Table 4).

16 **Discussion**

17 In the largest and longest follow-up study of adolescents with objectively measured body composition
18 and repeated fasting blood samples from mid-adolescence to young adulthood, the following were
19 observed. First, increased total body fat mass and trunk fat mass were separately associated with an
20 increased risk of hyperinsulinemia and insulin resistance. Second, higher total fat mass in mid-
21 adolescence may temporally precede higher insulin resistance by late adolescence which progressed to
22 a bidirectional relationship between total fat mass and insulin resistance by young adulthood. Third,
23 increasing lipids partially mediated the association between fat mass and insulin resistance. Lastly,
24 increased lean mass may protect against increased insulin resistance and hyperinsulinemia.

1 **Fat mass and metabolic alterations**

2 Over a quarter of a billion children and adolescents might be living with obesity by 2030 as estimated
3 by the World Obesity Federation.⁴ Previous evidence on the causal link between obesity and insulin
4 resistance in the pediatric population have relied on surrogate measures of obesity such as body mass
5 index and waist circumference but these measures poorly discriminate between fat mass and lean
6 mass.^{3,6-10} A direct measure of fat mass adiposity using dual-energy Xray absorptiometry has been
7 limited to cross-sectional studies in small sample-sized populations and a few short-term longitudinal
8 studies.^{8,10,11} Moreover, metabolic alteration such as glucose intolerance has been recorded in children
9 and adolescents who are overweight or obese but evidence in a normal-weight young population is
10 conflicting.^{5,9,11,12} Thus, large-scale long-term longitudinal studies of directly measured fat mass in
11 relation to metabolic indices are warranted to clarify the independent role of fat mass in metabolic
12 alteration especially in normal weight pediatric population.^{2,3,9,10}

13 In 564 primary school children from Canada aged 8-10 years and followed up for 2 years, who had at
14 least one parent with body mass index $>30\text{kg/m}^2$, every additional 1% of body fat measured with dual
15 energy Xray absorptiometry at baseline was associated with a 3.2% increase in insulin resistance
16 (HOMA-IR).¹² In this present study with a six times larger cohort and longer follow-up of 9 years, we
17 observed that both increased total fat mass and trunk fat mass were longitudinally associated with the
18 risk of worsening hyperinsulinemia and high insulin resistance during growth from ages 15 to 24 years.
19 This result was consistent in both normal-weight participants as well as those who are overweight or
20 obese, suggesting that fat mass at physiological concentration may be a strong risk factor for the
21 development of insulin resistance independent of physical activity. We observed that trunk fat mass
22 doubled the risk of high insulin resistance when compared to total fat mass buttressing that truncal

1 adiposity may be more metabolically deleterious.⁹ Nearly, all participants had attained puberty at
2 baseline age 15 years, and controlling for puberty did not alter the results (data not shown).¹⁷

3 Several experimental studies have postulated pathways for the relationship between obesity and insulin
4 resistance such as increased inflammation, dysfunctional adipose tissue, hormones, hypothalamus-
5 pituitary-adrenal-fat axis abnormalities, sympathetic nervous system overdrive, decreased brown or
6 beige adipocytes, lipotoxicity or lipoapoptosis, mitochondrial dysfunction, and endoplasmic reticulum
7 stress.^{9,10,15} Many of these mechanistic explanations are from animal models necessitating new
8 pathways in future research, especially in human studies.^{10,15} In the present study, we observed that
9 increased lipids especially triglyceride explained 9% of the relationship between fat mass and insulin
10 resistance in the cohort of largely normal-weight participants. Inflammation assessed with hsCRP did
11 not mediate the relationship between fat mass and insulin resistance, especially after accounting for
12 physical activity, nonetheless, further studies with other inflammatory markers are warranted.^{10,40,43,44}

13 Although the prevalence of smoking doubled during growth from mid-adolescence to young adulthood,
14 it only confounded the relationship between cumulative fat mass and insulin resistance by circa 4%
15 (data not shown). We observed that higher total fat mass in mid-adolescence temporally preceded
16 higher insulin resistance by late adolescence, however, higher total fat mass in late adolescence was
17 bidirectionally associated with higher insulin resistance in young adulthood. These findings suggest
18 that mid-adolescence might be an important time to interrupt the vicious cascade of higher fat mass and
19 insulin resistance but further experimental studies are needed.⁵ A recent large-scale longitudinal study
20 in more than 6000 children followed up until young adulthood concluded that engaging in at least 3-4
21 hours/day of light-intensity physical activity may decrease body fat mass by a maximum of 15%.⁴⁵ This
22 decrease may be clinically relevant in lowering insulin resistance and improving insulin sensitivity in
23 the young population.^{5,46}

1 **Lean mass and metabolic alterations**

2 In a cross-sectional study of US adults aged 41 years, skeletal muscle mass estimated by bioelectrical
3 impedance was associated with lower insulin resistance.⁴⁷ A recent review summarised that the
4 relationship between exercised-improved glucose homeostasis and increased skeletal muscle mass may
5 be concurrent but not necessarily causally associated.⁴⁸ In this study, we observed that increased lean
6 mass was associated with a 2% reduced risk of hyperinsulinemia and insulin resistance in the whole
7 cohort. This was confirmed in normal-weight participants among whom we observed that increased
8 lean mass was associated with lower insulin resistance. Furthermore, the mediating path analyses
9 suggest that the association of increased lean mass and insulin resistance, especially in participants who
10 are overweight may be explained by the residual effect of fat mass (85% mediation). We observed that
11 higher lean mass in mid-adolescence temporally preceded lower insulin resistance by late adolescence,
12 however, higher lean mass in late adolescence was bidirectionally associated with higher insulin
13 resistance in young adulthood possibly because of the significant increase in fat mass between late
14 adolescence and young adulthood. From age 15 to 17 years, an acute physiologic response to post-
15 pubertal changes¹⁷ was observed where lean mass potentially reduced insulin resistance and had a
16 carry-over cumulative effect although the relationship between lean mass and insulin resistance from
17 ages 17 to 24 years was positive rather than negative. In a recent study, we observed that increased
18 physical activity was paradoxically associated with reduced HDL-c and that physical activity was
19 associated with increased lean mass, reduced fat mass, and decreased insulin resistance.⁴⁹ However, the
20 52% suppressive effect of HDL on the association between lean mass and insulin resistance may relate
21 to liver metabolism.⁵⁰ Since HOMA-IR reflects hepatic insulin resistance and excessively elevated
22 HDL-c has been associated with liver damage, it is likely that the increased lean mass effect on
23 reducing insulin resistance is counteracted significantly by increased HDL-c after accounting for the

1 role of physical activity.⁵⁰ Increased levels of intramyocellular lipids content result in an accumulation
2 of intracellular fatty acyl CoAs or other fatty acid metabolites which modulate local glucose
3 metabolism and result in elevated insulin resistance of skeletal muscles.^{50,51} Overall, increased lean
4 mass from mid-adolescence might protect against worsening insulin resistance in the young population
5 and thus aerobic and resistance exercise interventions to increase muscle mass and decrease fat mass
6 are warranted.^{2,5,10,45,48,52}

7 **Strength and limitations**

8 The ALSPAC dataset provides an extensive array of gold-standard and repeated measures of body
9 composition and covariates throughout the follow-up period in a large paediatric population. Using
10 advanced statistical models, we examined the potential temporal and causal explanatory pathway and
11 consistency of the longitudinal findings for the first time in a large paediatric population. On the other
12 hand, the present study had some limitations. We did not measure insulin sensitivity and secretion
13 using gold-standard methods such as the clamp test,⁵³ given that the feasibility of these measures in
14 large epidemiologic studies is limited; nonetheless, we used surrogate whole-body insulin sensitivity
15 measure (SPISE) previously validated in the young population.²⁸ The computation of SPISE index
16 includes body mass index variable and body mass index assesses both fat mass and lean mass, hence
17 SPISE index is highly correlated (-0.75 to -0.80) with total fat mass and trunk fat mass. Therefore
18 SPISE index results should be cautiously interpreted, for example, an increased lean mass was
19 associated with decreased whole-body insulin sensitivity (SPISE index) but associated with increased
20 hepatic insulin sensitivity (HOMA-IR). Our participants were mostly White; therefore, we are unable
21 to generalize our findings to other racial and ethnic groups. Moreover, as with all observational studies,
22 residual biases due to unmeasured confounders may distort observed associations such as the
23 unavailability of dietary records and energy intake.

1 **Conclusion**

2 In a 9-year follow-up temporal and mediation study of several thousand adolescents, we observed that
3 progressive increase in fat mass temporally preceded insulin resistance and was associated with a
4 worsening risk of hyperinsulinemia and insulin resistance in both males and females as well as in
5 normal weight participants and those overweight and obese. An increase in triglyceride partially
6 explains the relationship between increased fat mass and insulin resistance. Increased trunk fat mass
7 doubled the risk of worsening insulin resistance when compared with total fat mass. Increased lean
8 mass was protective of insulin resistance, especially in normal-weight participants, and thus may be
9 targeted in future interventions. Mid-adolescence through late adolescence might be a crucial time for
10 interrupting the vicious cascade of higher fat mass and insulin resistance by young adulthood.

11 **Acknowledgments**

12 We are extremely grateful to all the families who took part in this study, the midwives for their help in
13 recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory
14 technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

15 **Funding**

16 The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of
17 Bristol provide core support for ALSPAC. The British Heart Foundation grant (CS/15/6/31468) funded
18 blood pressure, carotid-femoral pulse wave velocity, and Actigraph activity monitoring device
19 measurement at 24 years. The Medical Research Council grant (MR/M006727/1) supported smoking
20 data collection. A comprehensive list of grant funding is available on the ALSPAC website
21 (<http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf>); Dr Agbaje's
22 research group (Understanding FITness and Cardiometabolic Health In Little Darlings: *urFIT-child*)

1 was funded by the Jenny and Antti Wihuri Foundation (Grant no: 00180006); the North Savo Finnish
2 Cultural Foundation (Grant no: 65191835), central Finnish Cultural Foundation (Grant nos: 00200150,
3 and 00230190), Orion Research Foundation sr, Aarne Koskelo Foundation, Antti and Tyyne Soininen
4 Foundation, Paulo Foundation, Paavo Nurmi Foundation, Yrjö Jahnsson Foundation (Grant no:
5 20217390), Ida Montin Foundation, Kuopio University Foundation, Eino Räsänen Fund, Matti and
6 Vappu Maukonen Fund, and Alfred Kordelin Foundation (230082), the Finnish Foundation for
7 Cardiovascular Research (Grant no: 220021 and 230012). M. Henderson holds a Fonds de Recherche
8 du Québec – Santé Senior Investigator award. She is also the recipient of the Canadian Society of
9 Endocrinology and Metabolism Young Investigator Award.

10 **Conflict of interest:** None

11 **Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study;
12 collection, management, analysis, and interpretation of the data; preparation, review, or approval of the
13 manuscript; and decision to submit the manuscript for publication.

14 **Author Contributions:** Dr A.O. Agbaje had full access to all the data in the study and takes
15 responsibility for the integrity of the data and the accuracy of the data analysis. *Concept and design:*
16 A.O. Agbaje. *Acquisition, analysis, and interpretation of data:* A.O. Agbaje, *Drafting of the*
17 *manuscript:* A.O. Agbaje. *Critical revision of the manuscript for important intellectual content:* A.O.
18 Agbaje, C. Saner, J. Zhang, M. Henderson, and T-P. Tuomainen. *Statistical analysis:* A.O. Agbaje.
19 *Obtained funding:* A.O. Agbaje. This publication is the work of the authors and A.O. Agbaje will serve
20 as guarantor for the contents of this paper.

21 **Data Availability Statement:**

22 The informed consent obtained from ALSPAC participants does not allow the data to be made freely
23 available through any third-party maintained public repository. However, data used for this submission

1 can be made available on request to the ALSPAC Executive. The ALSPAC data management plan
2 describes in detail the policy regarding data sharing, which is through a system of managed open
3 access. Full instructions for applying for data access can be found here:
4 <http://www.bristol.ac.uk/alspac/researchers/access/>. The ALSPAC study website contains details of all
5 the data that are available (<http://www.bristol.ac.uk/alspac/researchers/our-data/>).

6 **Figure Legends**

7 **Figure 1** Trajectories of fat mass, lean mass, and insulin resistance (median and interquartile ranges)
8 from ages 15 through 24 years and autoregressive cross-lagged temporal causal associations of fat mass
9 with insulin resistance.

10 Cross lagged model was adjusted for sex, family history of hypertension/diabetes/high
11 cholesterol/vascular disease, socioeconomic status, sedentary time, light physical activity, moderate to
12 vigorous physical activity, and variables measured at ages 15 and 17 years such as age, low-density
13 lipoprotein cholesterol, triglyceride, high sensitivity C-reactive protein, high-density lipoprotein
14 cholesterol, heart rate, smoking status, systolic blood pressure, and lean mass. Skewed variables were
15 logarithmically transformed before analyses. A 2-sided P-value <0.05 is considered statistically
16 significant. β is standardized regression coefficient. Auto-regressive cross-lagged longitudinal analyses
17 were conducted using structural equation temporal causal path models. HOMA-IR, homeostatic model
18 assessment for insulin resistance.

19
20 **Figure 2** Longitudinal mediating effect of triglyceride (A) and low-density lipoprotein cholesterol (B)
21 in the associations of fat mass or lean mass with insulin resistance from ages 15 through 24 years.

1 Mediation structural equation model was adjusted for sex, family history of hypertension/diabetes/high
2 cholesterol/vascular disease, socioeconomic status, and time-varying covariates measured at both
3 baseline and follow-up such as age, heart rate, systolic blood pressure, smoking status, high-density
4 lipoprotein cholesterol, high-sensitivity C-reactive protein, sedentary time, light physical activity, and
5 moderate-to-vigorous physical activity, with additional adjustments for fat mass, lean mass, low-
6 density lipoprotein cholesterol, or triglyceride depending on the predictor or mediator. β is standardized
7 regression coefficient. P-value <0.05 were considered statistically significant. When the magnitude of
8 the longitudinal association between the predictor and outcome is decreased upon the inclusion of a
9 third variable, a mediation is confirmed. HOMA-IR, homeostatic model assessment for insulin
10 resistance; LDL-c, low-density lipoprotein cholesterol.

11

12 **References**

- 13 1. Jebeile H, Kelly AS, O'Malley G, Baur LA. Obesity in children and adolescents: epidemiology,
14 causes, assessment, and management. *lancet Diabetes Endocrinol.* 2022;10(5):351-365.
15 doi:10.1016/S2213-8587(22)00047-X
- 16 2. Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to
17 transform diabetes care and patient lives. *Lancet.* 2021;396(10267):2019-2082.
18 doi:10.1016/S0140-6736(20)32374-6
- 19 3. Hanssen H, Moholdt T, Bahls M, et al. Lifestyle interventions to change trajectories of obesity-
20 related cardiovascular risk from childhood onset to manifestation in adulthood: a joint scientific
21 statement of the task force for childhood health of the European Association of Preventive
22 Cardio. *Eur J Prev Cardiol.* Published online July 2023. doi:10.1093/eurjpc/zwad152
- 23 4. Lobstein T. Obesity prevention and the Global Syndemic: Challenges and opportunities for the
24 World Obesity Federation. *Obes Rev an Off J Int Assoc Study Obes.* 2019;20 Suppl 2:6-9.
25 doi:10.1111/obr.12888
- 26 5. Harnois-Leblanc S, Sylvestre MP, Van Hulst A, et al. Estimating causal effects of physical
27 activity and sedentary behaviours on the development of type 2 diabetes in at-risk children from
28 childhood to late adolescence: an analysis of the QUALITY cohort. *Lancet Child Adolesc Heal.*
29 2023;7(1):37-46. doi:10.1016/S2352-4642(22)00278-4
- 30 6. Juonala M, Magnussen CG, Berenson GS, et al. Childhood Adiposity, Adult Adiposity, and

- 1 Cardiovascular Risk Factors. *N Engl J Med.* 2011;365(20):1876-1885.
2 doi:10.1056/NEJMoa1010112
- 3 7. Jacobs DR, Woo JG, Sinaiko AR, et al. Childhood Cardiovascular Risk Factors and Adult
4 Cardiovascular Events. *N Engl J Med.* 2022;386(20):1877-1888. doi:10.1056/NEJMoa2109191
- 5 8. Chen F, Liu J, Hou D, et al. The Relationship between Fat Mass Percentage and Glucose
6 Metabolism in Children and Adolescents: A Systematic Review and Meta-Analysis. *Nutrients.*
7 2022;14(11). doi:10.3390/nu14112272
- 8 9. Davis SM, Sherk VD, Higgins J. Adiposity Is the Enemy: Body Composition and Insulin
9 Sensitivity. In: Zeitler PS, Nadeau KJ, eds. *Insulin Resistance: Childhood Precursors of Adult*
10 *Disease.* Springer International Publishing; 2020:133-153. doi:10.1007/978-3-030-25057-7_9
- 11 10. Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. *Circ Res.*
12 2020;126(11):1549-1564. doi:10.1161/CIRCRESAHA.119.315896
- 13 11. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and
14 adolescents with marked obesity. *N Engl J Med.* 2002;346(11):802-810.
15 doi:10.1056/NEJMoa012578
- 16 12. Henderson M, Benedetti A, Barnett TA, Mathieu ME, Deladoëy J, Gray-Donald K. Influence of
17 Adiposity, Physical Activity, Fitness, and Screen Time on Insulin Dynamics Over 2 Years in
18 Children. *JAMA Pediatr.* 2016;170(3):227-235. doi:10.1001/jamapediatrics.2015.3909
- 19 13. Agbaje AO. Mediating role of body composition and insulin resistance on the association of
20 arterial stiffness with blood pressure among adolescents: The ALSPAC study. *Front Cardiovasc*
21 *Med.* 2022;9:939125. doi:10.3389/fcvm.2022.939125
- 22 14. Tagi VM, Samvelyan S, Chiarelli F. An update of the consensus statement on insulin resistance
23 in children 2010. *Front Endocrinol (Lausanne).* 2022;13:1061524.
24 doi:10.3389/fendo.2022.1061524
- 25 15. Castro AVB, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and comorbidities?
26 Mechanisms of association. *Arq Bras Endocrinol Metabol.* 2014;58(6):600-609.
27 doi:10.1590/0004-2730000003223
- 28 16. Agbaje AO, Zachariah JP, Tuomainen TP. Arterial stiffness but not carotid intima-media
29 thickness progression precedes premature structural and functional cardiac damage in youth: A
30 7-year temporal and mediation longitudinal study. *Atherosclerosis.* 2023;380:117197.
31 doi:10.1016/j.atherosclerosis.2023.117197
- 32 17. Agbaje AO, Zachariah JP, Bamsa O, Odili AN, Tuomainen TP. Cumulative insulin resistance
33 and hyperglycaemia with arterial stiffness and carotid IMT progression in 1779 adolescents: A
34 9-Year Longitudinal Cohort Study. *Am J Physiol Endocrinol Metab.* 2023;324(3):E268-E278.
35 doi:10.1152/ajpendo.00008.2023
- 36 18. Pahkala K, Laitinen TT, Niinikoski H, et al. Effects of 20-year infancy-onset dietary counselling
37 on cardiometabolic risk factors in the Special Turku Coronary Risk Factor Intervention Project
38 (STRIP): 6-year post-intervention follow-up. *Lancet Child Adolesc Heal.* 2020;4(5):359-369.
39 doi:10.1016/S2352-4642(20)30059-6

- 1 19. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
2 community of software platform partners. *J Biomed Inform.* 2019;95:103208.
3 doi:10.1016/j.jbi.2019.103208
- 4 20. Boyd A, Golding J, Macleod J, et al. Cohort profile: The 'Children of the 90s'-The index
5 offspring of the avon longitudinal study of parents and children. *Int J Epidemiol.*
6 2013;42(1):111-127. doi:10.1093/ije/dys064
- 7 21. Fraser A, Macdonald-wallis C, Tilling K, et al. Cohort profile: The avon longitudinal study of
8 parents and children: ALSPAC mothers cohort. *Int J Epidemiol.* 2013;42(1):97-110.
9 doi:10.1093/ije/dys066
- 10 22. Northstone K, Lewcock M, Groom A, et al. The Avon Longitudinal Study of Parents and
11 Children (ALSPAC): an update on the enrolled sample of index children in 2019. *Wellcome*
12 *Open Res.* 2019;4:51. doi:10.12688/wellcomeopenres.15132.1
- 13 23. Agbaje AO, Barker AR, Tuomainen TP. Effects of Arterial Stiffness and Carotid Intima- Media
14 Thickness Progression on the Risk of Overweight/Obesity and Elevated Blood Pressure/
15 Hypertension: a Cross-Lagged Cohort Study. *Hypertension.* 2022;79(1):159-169.
16 doi:10.1161/HYPERTENSIONAHA.121.18449
- 17 24. Agbaje AO, Barker AR, Mitchell GF, Tuomainen TP. Effect of arterial stiffness and carotid
18 intima-media thickness progression on the risk of dysglycemia, insulin resistance, and
19 dyslipidaemia: a temporal causal longitudinal study. *Hypertension.* 2022;79(3):667-678.
20 doi:10.1161/HYPERTENSIONAHA.121.18754
- 21 25. Agbaje AO, Barker AR, Tuomainen TP. Cumulative muscle mass and blood pressure but not fat
22 mass drives arterial stiffness and carotid intima-media thickness progression in the young
23 population and is unrelated to vascular organ damage. *Hypertens Res.* 2023;46:984-999.
24 doi:10.1038/s41440-022-01065-1
- 25 26. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of
26 Medical Care in Diabetes-2020. *Diabetes Care.* 2020;43(Suppl 1):S14-S31. doi:10.2337/dc20-
27 S002
- 28 27. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care.*
29 2004;27(6):1487-1495. doi:10.2337/diacare.27.6.1487
- 30 28. Paulmichl K, Hatunic M, Højlund K, et al. Modification and Validation of the Triglyceride-to-
31 HDL Cholesterol Ratio as a Surrogate of Insulin Sensitivity in White Juveniles and Adults
32 without Diabetes Mellitus: The Single Point Insulin Sensitivity Estimator (SPISE). *Clin Chem.*
33 2016;62(9):1211-1219. doi:10.1373/clinchem.2016.257436
- 34 29. Agbaje AO. Increasing lipids with risk of worsening cardiac damage in 1595 adolescents: A 7-
35 year longitudinal and mediation study. *Atherosclerosis.* Published online 2023:117440.
36 doi:https://doi.org/10.1016/j.atherosclerosis.2023.117440
- 37 30. Frysz M, Howe LD, Tobias JH, Paternoster L. Using SITAR (Superimposition by translation
38 and rotation) to estimate age at peak height velocity in avon longitudinal study of parents and
39 children [version 2; referees: 2 approved]. *Wellcome Open Res.* 2018;3:90.
40 doi:10.12688/wellcomeopenres.14708.2

- 1 31. Agbaje AO, Barker AR, Tuomainen TP. Cardiorespiratory Fitness, Fat Mass, and
2 Cardiometabolic Health with Endothelial Function, Arterial Elasticity, and Stiffness. *Med Sci
3 Sport Exerc.* 2022;54(1):141-152. doi:10.1249/mss.0000000000002757
- 4 32. Agbaje AO. Associations of accelerometer-based sedentary time, light physical activity and
5 moderate-to-vigorous physical activity with resting cardiac structure and function in adolescents
6 according to sex, fat mass, lean mass, BMI, and hypertensive status. *Scand J Med Sci Sports.*
7 2023;33(8):1399-1411. doi:10.1111/sms.14365
- 8 33. Lee H, Cashin AG, Lamb SE, et al. A Guideline for Reporting Mediation Analyses of
9 Randomized Trials and Observational Studies: The AGRReMA Statement. *JAMA.*
10 2021;326(11):1045-1056. doi:10.1001/jama.2021.14075
- 11 34. MacKinnon DP, Krull JL, Lockwood CM. Equivalence of the mediation, confounding and
12 suppression effect. *Prev Sci.* 2000;1(4):173-181. doi:10.1023/a:1026595011371
- 13 35. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing
14 indirect effects in multiple mediator models. *Behav Res Methods.* 2008;40:879-891.
15 doi:10.3758/BRM.40.3.879
- 16 36. Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple
17 mediation models. *Behav Res Methods, Instruments, Comput.* 2004;36:717-731.
18 doi:10.3758/BF03206553
- 19 37. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical
20 activity and sedentary behaviour. *Br J Sports Med.* 2020;54(24):1451-1462.
21 doi:10.1136/bjsports-2020-102955
- 22 38. DiPietro L, Al-Ansari SS, Biddle SJH, et al. Advancing the global physical activity agenda:
23 recommendations for future research by the 2020 WHO physical activity and sedentary
24 behavior guidelines development group. *Int J Behav Nutr Phys Act.* 2020;17(1):143.
25 doi:10.1186/s12966-020-01042-2
- 26 39. Hill JO, Wyatt HR. Role of physical activity in preventing and treating obesity. *J Appl Physiol.*
27 2005;99(2):765-770. doi:10.1152/jappphysiol.00137.2005
- 28 40. Agbaje AO, Barmi S, Sansum KM, Baynard T, Barker AR, Tuomainen TP. Temporal
29 longitudinal associations of carotid-femoral pulse wave velocity and carotid intima-media
30 thickness with resting heart rate and inflammation in youth. *J Appl Physiol.* 2023;134(3):657-
31 666. <https://doi.org/10.1152/jappphysiol.00701.2022>
- 32 41. Golding G, Pembrey P, Jones J. ALSPAC - The Avon Longitudinal Study of Parents and
33 Children I. Study methodology. *Paediatr Perinat Epidemiol.* 2001;15(1):74-87.
34 doi:10.1046/j.1365-3016.2001.00325.x
- 35 42. Agbaje AO, Saner C, Zhang J, Henderson M, Tuomainen TP. DEXA-based Fat Mass with the
36 Risk of Worsening Insulin Resistance in Adolescents: A 9-Year Temporal and Mediation
37 Study_Supplemental Appendix. *Figshare.* Published online 2023.
38 doi:10.6084/m9.figshare.24746112
- 39 43. Agbaje AO. Longitudinal Mediating effect of Fatmass and Lipids on Sedentary Time, Light PA,
40 and MVPA with Inflammation in Youth. *J Clin Endocrinol Metab.* 2023;108(12):3250–3259.

- 1 doi:10.1210/clinem/dgad354
- 2 44. Mansell T, Bekkering S, Longmore D, et al. Change in adiposity is associated with change in
3 glycoprotein acetyls but not hsCRP in adolescents with severe obesity. *Obes Res Clin Pract.*
4 2023;17(4):343-348. doi:10.1016/j.orcp.2023.08.003
- 5 45. Agbaje AO, Perng W, Tuomainen TP. Effects of Accelerometer-based Sedentary Time and
6 Physical Activity on DEXA-measured Fat Mass in 6059 Children. *Nat Commun.* 2023;14:8232.
7 doi:10.1038/s41467-023-43316-w
- 8 46. Lister NB, Baur LA, Felix JF, et al. Child and adolescent obesity. *Nat Rev Dis Prim.*
9 2023;9(1):24. doi:10.1038/s41572-023-00435-4
- 10 47. Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin
11 resistance and prediabetes. Findings from the third National Health and Nutrition Examination
12 Survey. *J Clin Endocrinol Metab.* 2011;96(9):2898-2903. doi:10.1210/jc.2011-0435
- 13 48. Paquin J, Lagacé JC, Brochu M, Dionne IJ. Exercising for Insulin Sensitivity - Is There a
14 Mechanistic Relationship With Quantitative Changes in Skeletal Muscle Mass? *Front Physiol.*
15 2021;12:656909. doi:10.3389/fphys.2021.656909
- 16 49. Agbaje AO. Associations of Sedentary Time and Physical Activity from Childhood with Lipids:
17 A 13-Year Mediation and Temporal Study. *J Clin Endocrinol Metab.* Published online
18 2023:dgad688. doi:10.1210/clinem/dgad688
- 19 50. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev.*
20 2018;98(4):2133-2223. doi:10.1152/physrev.00063.2017
- 21 51. Maggs DG, Jacob R, Rife F, et al. Interstitial fluid concentrations of glycerol, glucose, and
22 amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in
23 skeletal muscle. *J Clin Invest.* 1995;96(1):370-377. doi:10.1172/JCI118043
- 24 52. Paluch AE, Boyer WR, Franklin BA, et al. Resistance Exercise Training in Individuals With and
25 Without Cardiovascular Disease: 2023 Update: A Scientific Statement From the American
26 Heart Association. *Circulation.* Published online December 2023.
27 doi:10.1161/CIR.0000000000001189
- 28 53. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion
29 and action in subjects with impaired fasting glucose and impaired glucose tolerance: results
30 from the Veterans Administration Genetic Epidemiology Study. *Diabetes.* 2006;55(5):1430-
31 1435. doi:10.2337/db05-1200

1 **Table 1** Descriptive characteristics of 3160 participants who had complete body composition and
 2 insulin resistance at age 15-years clinic visits.

| Age at clinic visits/follow-up Variables | 15 years | | | 17 years | | | 24 years | | |
|---|---------------|-----------------|---------|---------------|-----------------|---------|---------------|-----------------|---------|
| | Male (n=1546) | Female (n=1614) | P-value | Male (n=1167) | Female (n=1350) | P-value | Male (n=787) | Female (n=1093) | P-value |
| Anthropometry | | | | | | | | | |
| Age at clinic visit (years), mean (SD) | 15.41 (0.26) | 15.43 (0.28) | 0.077 | 17.74 (0.38) | 17.74 (0.37) | 0.876 | 24.56 (0.78) | 24.44 (0.75) | 0.001 |
| Height (m), mean (SD) | 1.75 (0.08) | 1.65 (0.06) | <0.001 | 1.79 (0.07) | 1.66 (0.06) | <0.0001 | 1.80 (0.07) | 1.66 (0.06) | <0.0001 |
| *Weight (kg) | 62.80 (13.5) | 58.0 (12.3) | <0.0001 | 70.60 (14.75) | 61.00 (13.68) | <0.0001 | 79 (17.67) | 65.30 (17.30) | <0.0001 |
| Attained puberty (n,%) | 1400 (95.4) | 1519 (>99.9) | <0.001 | NA | | | NA | | |
| Body composition | | | | | | | | | |
| *Total fat mass (kg) | 8.67 (7.51) | 17.59 (9.07) | <0.0001 | 10.91 (10.41) | 19.71 (10.19) | <0.0001 | 18.35 (11.43) | 22.18 (12.32) | <0.0001 |
| *Trunk fat mass (kg) | 3.79 (3.69) | 8.05 (5.12) | <0.0001 | 5.63 (5.68) | 9.68 (5.67) | <0.0001 | 9.09 (6.78) | 10.06 (6.92) | <0.001 |
| *Lean mass (kg) | 50.34 (8.64) | 36.99 (4.90) | <0.0001 | 55.39 (8.43) | 37.96 (5.08) | <0.0001 | 56.74 (10.22) | 41.05 (6.71) | <0.0001 |
| *Body mass index (kg/m ²) | 20.42 (3.45) | 21.23 (3.97) | <0.001 | 21.71 (4.09) | 22.18 (4.05) | 0.004 | 24.22 (4.95) | 23.65 (5.95) | 0.146 |
| Overweight-body mass index 25 – 29.9kg/m ² | 136 (8.8) | 200 (12.4) | <0.001 | 171 (14.9) | 212 (16.1) | 0.006 | 248 (31.6) | 233 (21.6) | 0.758 |
| Obese-body mass index >29.9kg/m ² | 36 (2.3) | 59 (3.7) | <0.001 | 56 (4.9) | 97 (7.4) | 0.006 | 81 (10.3) | 171 (15.9) | 0.758 |
| Fasting plasma metabolic indices | | | | | | | | | |
| High-density lipoprotein (mmol/L), mean (SD) | 1.22 (0.27) | 1.36 (0.30) | <0.001 | 1.19 (0.25) | 1.35 (0.31) | <0.001 | 1.40 (0.36) | 1.66 (0.42) | <0.001 |
| Low-density lipoprotein (mmol/L), mean (SD) | 1.99 (0.52) | 2.18 (0.57) | <0.001 | 1.99 (0.56) | 2.21 (0.64) | <0.001 | 2.47 (0.76) | 2.43 (0.76) | 0.333 |
| *Triglyceride (mmol/L) | 0.72 (0.38) | 0.76 (0.37) | <0.001 | 0.74 (0.37) | 0.75 (0.38) | 0.502 | 0.88 (0.55) | 0.80 (0.42) | <0.001 |
| Glucose (mmol/L), mean (SD) | 5.30 (0.40) | 5.13 (0.36) | <0.001 | 5.13 (0.40) | 4.90 (0.37) | <0.001 | 5.47 (0.79) | 5.21 (0.56) | <0.001 |
| Hyperglycemia (>6.1 mmol/L) (n,%) | 18 (1.2) | 11 (0.7) | 0.191 | 12 (1.2) | 6 (0.6) | 0.158 | 58 (7.8) | 36 (3.8) | <0.001 |
| *Insulin (mU/L) | 8.18 (4.88) | 9.74 (5.66) | <0.0001 | 5.95 (3.97) | 7.24 (4.32) | <0.0001 | 7.11 (4.94) | 7.84 (5.67) | <0.001 |
| Hyperinsulinemia (>11.78mU/L) (n, %) | 304 (19.7) | 516 (32.0) | <0.001 | 115 (11.6) | 152 (14.9) | 0.030 | 133 (17.9) | 206 (21.8) | 0.050 |
| *Insulin resistance (HOMA-IR) | 1.95 (1.21) | 2.22 (1.35) | <0.0001 | 1.36 (1.00) | 1.59 (1.01) | <0.001 | 1.69 (1.24) | 1.79 (1.43) | 0.119 |
| Insulin sensitivity (SPISE) | 9.31 (2.10) | 8.92 (2.06) | <0.001 | 8.49 (1.97) | 8.51 (2.10) | 0.859 | 7.44 (1.97) | 7.95 (2.17) | <0.001 |
| *High sensitivity C-reactive protein (mg/L) | 0.38 (0.67) | 0.39 (0.67) | 0.574 | 0.48 (0.79) | 0.65 (1.40) | <0.001 | 0.65 (1.19) | 0.98 (1.99) | <0.001 |
| Vascular measures | | | | | | | | | |
| Heart rate (beat/mins), mean (SD) | 71 (12) | 77 (12) | <0.001 | 63 (9) | 67 (10) | <0.001 | 65 (10) | 68 (10) | <0.001 |
| Systolic blood pressure (mmHg), mean (SD) | 127 (10) | 121 (11) | <0.001 | 120 (9) | 110 (8) | <0.001 | 123 (10) | 112 (9) | <0.001 |
| Diastolic blood pressure (mmHg), mean (SD) | 68 (9) | 66 (8) | <0.001 | 63 (6) | 65 (6) | <0.001 | 68 (8) | 66 (8) | <0.001 |
| Lifestyle and sociodemographic factors | | | | | | | | | |
| Smoking status (n, %) | 208 (13.9) | 318 (20) | <0.001 | 251 (25.1) | 338 (29.2) | 0.033 | 226 (29.2) | 301 (27.7) | 0.498 |
| Family history of H-D-C-V (n,%) | 326 (29.2) | 386 (29.8) | 0.788 | NA | | | NA | | |
| Sedentary time (min/day), mean (SD) | 353 (74) | 361 (70) | 0.009 | 461 (93) | 482 (82) | <0.001 | 529 (79) | 520 (85) | 0.250 |
| Light physical activity (min/day), mean (SD) | 368 (60) | 369 (58) | 0.618 | 290 (67) | 272 (64) | <0.001 | 142 (56) | 149 (53) | 0.163 |
| MVPA (min/day), mean | 67 (33) | 48 (23) | <0.001 | 56 (30) | 41 (30) | <0.001 | 56 (35) | 49 (28) | 0.030 |

| | | | | | |
|---------------------------------------|----------------|----------------|-------|----|----|
| (SD) | | | | | |
| Ethnicity- White (n,%) | 1359 (95.8) | 1409 (96.2) | 0.356 | NA | NA |
| Maternal social economic status (n,%) | | | 0.077 | NA | NA |
| Professional | 59 (8.1) | 28 (4.0) | | | |
| Managerial and technical | 293 (40) | 266 (38.2) | | | |
| Skilled non-manual | 239 (32.7) | 261 (37.5) | | | |
| Skilled manual | 13 (1.8) | 18 (2.6) | | | |
| Partly skilled | 105 (14.3) | 98 (14.1) | | | |
| Unskilled | 23 (3.1) | 25 (3.6) | | | |

The values are means (standard deviations) and *median (interquartile range) except for lifestyle factors and ethnicity. Differences between sexes were tested using Student's t-test for normally distributed continuous variables, Mann-Whitney U test for skewed continuous variables, Chi-square test for dichotomous variable, and analysis of covariance for multicategory variable. A 2-sided P-value <0.05 is considered statistically significant. H-D-C-V, hypertension/diabetes/high cholesterol/vascular disease; Homeostatic model assessment of insulin resistance was computed from (fasting insulin×fasting glucose/22.5); Single Point Insulin Sensitivity Estimator (SPISE) was computed from $[600 \times \text{high-density lipoprotein cholesterol (HDL-c)}^{0.185} / (\text{Triglyceride}^{0.2} \times \text{body mass index}^{1.338})]$. MVPA, moderate-to-vigorous physical activity; NA, not available/applicable; p-value for sex differences.

Table 2 Longitudinal associations of cumulative body composition with the risk of progressive hyperglycemia, hyperinsulinemia, and elevated insulin resistance from ages 15 through 24 years among 3160 participants

| N=3160 | Hyperglycemia (>6.1 mmol/L) | | Hyperinsulinemia (>11.78mU/L) | | Elevated Insulin resistance | |
|--|-----------------------------|---------|-------------------------------|---------|-----------------------------|---------|
| | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Continuous cumulative predictor variables from ages 15 – 24 years | | | | | | |
| Total fat mass (kg) | | | | | | |
| Model 1 | 1.06 (1.05 – 1.07) | <0.0001 | 1.08 (1.07 – 1.09) | <0.0001 | 1.10 (1.09 – 1.11) | <0.0001 |
| Model 2 | 1.04 (1.03 – 1.05) | <0.0001 | 1.08 (1.07 – 1.09) | <0.0001 | 1.12 (1.11 – 1.13) | <0.0001 |
| Model 3 | 1.04 (1.03 – 1.05) | <0.0001 | 1.09 (1.08 – 1.09) | <0.0001 | 1.12 (1.11 – 1.13) | <0.0001 |
| Trunk fat mass (kg) | | | | | | |
| Model 1 | 1.10 (1.09 – 1.12) | <0.0001 | 1.15 (1.14 – 1.17) | <0.0001 | 1.19 (1.17 – 1.21) | <0.0001 |
| Model 2 | 1.08 (1.07 – 1.10) | <0.0001 | 1.14 (1.12 – 1.16) | <0.0001 | 1.21 (1.19 – 1.23) | <0.0001 |
| Model 3 | 1.07 (1.06 – 1.09) | <0.0001 | 1.13 (1.13 – 1.16) | <0.0001 | 1.21 (1.19 – 1.23) | <0.0001 |
| Lean mass (kg) | | | | | | |
| Model 1 | 1.01 (0.99 – 1.02) | 0.190 | 0.99 (0.99 – 1.01) | 0.504 | 1.00 (0.99 – 1.01) | 0.461 |
| Model 2 | 1.01 (0.99 – 1.01) | 0.494 | 0.98 (0.98 – 0.99) | 0.004 | 0.98 (0.98 – 0.99) | 0.010 |
| Model 3 | 1.01 (0.99 – 1.02) | 0.238 | 0.98 (0.98 – 0.99) | 0.007 | 0.98 (0.98 – 0.99) | 0.009 |
| Body mass index (kg/m²) | | | | | | |
| Model 1 | 1.08 (1.06 – 1.11) | <0.001 | 1.17 (1.14 – 1.19) | <0.0001 | 1.21 (1.19 – 1.23) | <0.0001 |

| | | | | | | |
|-------------------|--------------------|-------------------|--------------------|-------------------|--------------------|-------------------|
| <i>Model</i> 2 | 1.07 (1.05 – 1.09) | <0.0001 | 1.18 (1.15 – 1.20) | <0.0001 | 1.27 (1.24 – 1.29) | <0.0001 |
| <i>Model</i> 3 | 1.07 (1.05 – 1.09) | <0.001 | 1.19 (1.16 – 1.21) | <0.0001 | 1.26 (1.23 – 1.27) | <0.0001 |

1 For continuous variable analyses, Model 1 was unadjusted. Model 2 was adjusted for sex, and other time-varying
2 covariates measured at both baseline and follow-up such as age, low-density lipoprotein cholesterol, triglyceride,
3 high sensitivity C-reactive protein, high-density lipoprotein cholesterol, heart rate, systolic blood pressure, in
4 addition to glucose, insulin, fat mass or lean mass depending on the exposure or outcome. Model 3 was an additional
5 adjustment for lifestyle factors viz, sedentary time, light physical activity, moderate to vigorous physical activity,
6 smoking status, family history of hypertension/diabetes/high cholesterol/vascular disease, socioeconomic status.
7 Odds ratio were computed from the generalized linear mixed-effect model with logit link for repeated measures; CI,
8 confidence interval. A 2-sided P-value <0.05 is considered statistically significant. Multiple testing was corrected
9 with Sidak correction. Multiple imputations were used to account for missing variables. Body mass index predictor
10 model was not adjusted for lean mass and fat mass, Insulin resistance outcome model was not adjusted for insulin
11 and glucose. Homeostatic model assessment of insulin resistance was computed from (fasting insulin×fasting
12 glucose/22.5). Elevated insulin resistance describes $\geq 75^{\text{th}}$ percentile.
13
14
15

16 **Table 3** Auto-regressive cross-lagged temporal causal longitudinal analyses of fat mass, lean
17 mass, insulin resistance in relations with insulin resistance at 15, 17, and 24 years of age
18

| <i>3160 participants</i> | | | | | |
|---|----------|---------------------------|-----------|-------------------|--|
| Insulin resistance | | | | | |
| <i>Auto-regressive</i> | B | β | SE | p-value | |
| Total FM T1 \Rightarrow Total FM T2 | 0.834 | 0.863 | 0.009 | <0.0001 | |
| Total FM T2 \Rightarrow Total FM T3 | 0.543 | 0.827 | 0.008 | <0.0001 | |
| Lean mass T1 \Rightarrow Lean mass T2 | 0.744 | 0.667 | 0.008 | <0.0001 | |
| Lean mass T2 \Rightarrow Lean mass T3 | 0.921 | 0.203 | 0.010 | <0.0001 | |
| HOMA-IR T1 \Rightarrow HOMA-IR T2 | 0.251 | 0.258 | 0.016 | <0.0001 | |
| HOMA-IR T2 \Rightarrow HOMA-IR T3 | 0.289 | 0.213 | 0.034 | <0.0001 | |
| <i>Cross-lagged</i> | | | | | |
| Total FM T1 \Rightarrow HOMA-IR T2 | 0.209 | 0.261 | 0.017 | <0.0001 | |
| HOMA-IR T1 \Rightarrow Total FM T2 | -0.002 | -0.002 | -0.250 | 0.803 | |
| Total FM T2 \Rightarrow HOMA-IR T3 | 0.266 | 0.237 | 8.648 | <0.0001 | |
| HOMA-IR T2 \Rightarrow Total FM T3 | 0.050 | 0.064 | 0.009 | <0.0001 | |
| Lean mass T1 \Rightarrow HOMA-IR T2 | -0.141 | -0.055 | 0.064 | <0.028 | |
| HOMA-IR T1 \Rightarrow Lean mass T2 | 0.002 | 0.004 | 0.002 | 0.421 | |
| Lean mass T2 \Rightarrow HOMA-IR T3 | 0.251 | 0.081 | 0.091 | 0.006 | |
| HOMA-IR T2 \Rightarrow Lean mass T3 | 0.009 | 0.022 | 0.004 | 0.020 | |

19 Time T1, 15 years of age; Time T2, 17 years of age; Time T3, 24 years of age. B, unstandardized regression; β ,
20 standardized regression; FM, fat mass; HOMA-IR, homeostatic model assessment of insulin resistance; SE, standard
21 error. Model was adjusted for baseline age, sex, low-density lipoprotein cholesterol, triglyceride, high sensitivity C-
22 reactive protein, high-density lipoprotein cholesterol, heart rate, smoking status, systolic blood pressure, family
23 history of hypertension/diabetes/high cholesterol/vascular disease, socioeconomic status, sedentary time, light
24 physical activity, moderate to vigorous physical activity, in addition to fat mass or lean mass depending on predictor.
25 Skewed variables were logarithmically transformed before analyses. A 2-sided P-value <0.05 is considered
26 statistically significant. Auto-regressive cross-lagged longitudinal analyses were conducted using structural equation
27 temporal causal path models.
28
29

Table 4 Mediating or suppressing role of cumulative lipids, inflammation, systolic blood pressure on the longitudinal associations of total fat mass and lean mass with and insulin resistance progression from ages 15 through 24 years of 3160 participants.

| Cumulative total fat mass | Cumulative insulin resistance from ages 15 – 24 years | | | | | | |
|---------------------------|---|----------------|--------------------------|----------------|--------------------------|----------------|------------------------------|
| | Total effect | | Direct effect | | Indirect effect | | Mediation or Suppression (%) |
| <i>Mediators</i> | β (95% CI) | <i>p-value</i> | β (95% CI) | <i>p-value</i> | β (95% CI) | <i>p-value</i> | |
| HDL | 0.481 (0.465 – 0.498) | 0.002 | 0.462 (0.446 – 0.478) | 0.002 | 0.019 (0.015 – 0.023) | 0.001 | 4.0 mediation |
| LDL | 0.442 (0.425 – 0.459) | 0.002 | 0.429 (0.410 – 0.447) | 0.002 | 0.013 (0.009 – 0.018) | 0.001 | 2.9 mediation |
| Triglyceride | 0.412 (0.395 – 0.431) | 0.002 | 0.375 (0.356 – 0.391) | 0.002 | 0.038 (0.029 – 0.047) | 0.001 | 9.2 mediation |
| High-sensitivity CRP | 0.456 (0.440 – 0.473) | 0.001 | 0.463 (0.445 – 0.482) | 0.002 | -0.007 (-0.015 – -0.000) | 0.067 | 1.5 |
| Systolic blood pressure | 0.368 (0.353 – 0.387) | 0.001 | 0.357 (0.342 – 0.375) | 0.001 | 0.011 (0.007 – 0.015) | 0.002 | 3.0 mediation |
| Lean mass | 0.468 (0.448 – 0.489) | 0.001 | 0.462 (0.444 – 0.480) | 0.001 | 0.006 (0.002 – 0.010) | 0.004 | 1.3 mediation |
| Cumulative lean mass | Cumulative insulin resistance from ages 15 – 24 years | | | | | | |
| <i>Mediators</i> | β (95% CI) | <i>p-value</i> | β (95% CI) | <i>p-value</i> | β (95% CI) | <i>p-value</i> | |
| HDL | -0.073 (-0.095 – -0.050) | 0.002 | -0.111 (-0.132 – -0.087) | 0.002 | 0.038 (0.030 – 0.047) | 0.001 | 52.1 suppression |
| LDL | -0.081 (-0.101 – -0.057) | 0.003 | -0.048 (-0.069 – -0.025) | 0.003 | -0.033 (-0.042 – -0.024) | 0.002 | 40.7 mediation |
| Triglyceride | -0.081 (-0.105 – -0.055) | 0.002 | -0.089 (-0.109 – -0.068) | 0.002 | 0.008 (-0.010 – -0.021) | 0.349 | 10 |
| High-sensitivity CRP | -0.075 (-0.096 – -0.051) | 0.002 | -0.067 (-0.088 – -0.041) | 0.003 | -0.008 (-0.015 – -0.003) | 0.008 | 10.6 mediation |
| Systolic blood pressure | 0.009 (-0.011 – -0.031) | 0.413 | -0.076 (-0.096 – -0.056) | 0.002 | 0.085 (0.078 – 0.092) | 0.002 | 944.4 |
| Fat mass | 0.197 (0.172 – 0.226) | 0.001 | 0.030 (0.009 – 0.051) | 0.005 | 0.163 (0.152 – 0.184) | 0.002 | 84.5 mediation |

10 Mediation structural equation model was adjusted for sex, family history of
 11 hypertension/diabetes/high cholesterol/vascular disease, socioeconomic status, and time-varying
 12 covariates measured at both baseline and follow-up such as age, heart rate, smoking status, light
 13 physical activity and moderate-to-vigorous physical activity, with additional adjustments for fat
 14 mass, lean mass, insulin resistance, high sensitivity C-reactive protein, high-density lipoprotein
 15 cholesterol, low-density lipoprotein cholesterol, or triglyceride depending on the mediator. β is
 16 standardized regression co-efficient. *p*-value <0.05 were considered statistically significant.
 17 When the magnitude of the longitudinal association between the predictor and outcome is
 18 increased upon inclusion of a third variable, a suppression is confirmed; however, when
 19 decreased it is mediation.




Figure 1
339x190 mm (DPI)




Figure 2
339x190 mm (DPI)

1
2
3
4

5
6
7